CLNP023Q12301
Brief description of study
The purpose of this study is to evaluate the efficacy, safety, and tolerability of iptacopan in male and female patients 18-75 years of age, with anti-acetylcholine receptor antibody-positive (AChR+) gMG who are on stable, standard-of-care (SOC) treatment. The study aims to evaluate whether treatment with iptacopan will result in the reduction of the total score in Myasthenia Gravis Activity of Daily Living (MG-ADL) scale as compared to placebo.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
